Docoh
Loading...

LPTX Leap Therapeutics

Filed: 13 Aug 21, 7:10am

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT 

Pursuant to Section 13 or 15(D) 

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 13, 2021

 

 

 

Leap Therapeutics, Inc. 

(Exact name of registrant as specified in its charter)

 

 

 

Delaware001-3799027-4412575
(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

47 Thorndike Street, Suite B1-1

Cambridge, MA

02141
(Address of principal executive offices)(Zip Code)
    

Registrant’s telephone number, including area code: (617) 714-0360

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each classTrading Symbol(s)Name of each exchange on which
registered
Common Stock, par value $0.001LPTXNasdaq Global Market

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition

 

On August 13, 2021, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2021 and provided upcoming Company milestones.  The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)            Exhibits.

 

Exhibit
Number
 Description
   
99.1  Press Release of Leap Therapeutics, Inc. dated August 13, 2021.
104  Cover Page Interactive Data File

 

- 2 -

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 LEAP THERAPEUTICS, INC.
  
  
Dated: August 13, 2021By:/s/ Douglas E. Onsi
 Name:Douglas E. Onsi
 Title:Chief Executive Officer and President